Pioneering ApproachesDelivering Innovation

We are committed to alleviating human suffering through the development of novel therapies.

We have a marketed product, DACOGEN^®, indicated for the treatment of myelodysplastic syndromes. Dacogen is marketed by Eisai in North America and Janssen Cilag GmbH, International, a Johnson & Johnson company, in the rest of the world.

And, as an innovative leader in small-molecule drug discovery, we have a strong portfolio of proprietary and partnered drug products that are in clinical development.